–News Direct–
PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore Immuno-Oncology Profiling (IOP) and IHC Explore1 to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries.
As cancer rates continue to rise, the demand for advanced precision medicine tools that provide accurate biological insights has never been greater. Our mission to make a difference in patient lives is unwavering, and these new products showcase our commitment to providing researchers with the tools they need to make meaningful advancements in cancer research, treatment and care, said Andy Beck, PathAI CEO. We're thrilled to introduce these two groundbreaking products ahead of the American Society of Clinical Oncology annual meeting.
PathExplore IOP: H&E-Based Immune Phenotyping
The composition of the tumor immune microenvironment plays a crucial role in characterizing tumors likely to respond to immunotherapy. PathExplore IOP expedites characterization of immune phenotypes by quantifying tumor infiltrating lymphocytes (TILs) and their spatial distribution using routine hematoxylin and eosin (H&E) samples. With this new product, researchers have the ability to quantify TIL spatial arrangements within tumor core and periphery, and gain insights around the samples immune inflamed, desert, or excluded characteristics.
PathExplore IOP was designed specifically to quantify patterns of immune infiltration characteristic of a strong immune response, and ultimately improved patient survival. Immune infiltration has been previously shown to be prognostic of positive outcomes, however; standardized and scalable approaches for investigating these phenotypes remained elusive.
PathExplore IOP illustrates the power of AI by visually interrogating the dynamics between cancer cells and immune cells with unparalleled resolution for highly accurate and efficient immune phenotype classification, said Benjamin Glass, VP of Product & Translational Research. Researchers can now access insights at scale to better inform biomarker strategies for patient stratification and mechanisms of response and resistance.
PathExplore IOP will be featured in a poster presentation at the upcoming ASCO 2024 meeting, demonstrating the products application for stratification of patient response to checkpoint inhibitors in non-small cell lung cancer.
IHC Explore: AI-Powered Biomarker Quantification
Immunohistochemistry (IHC) is a widely utilized approach for identifying biomarkers unique to certain cancers, informing treatment strategies, measuring prognosis, and patient classification for clinical trials. IHC scoring in the early clinical settings can be time-consuming, subjective, and low-resolution. Especially in early stage biomarker development, defining an optimal scoring system for a novel IHC assay can be complex. IHC Explore fills a need for spatial quantification of IHC biomarkers in single-cell resolution with broad target compatibility.
IHC Explore provides a panel of standardized and structured features that quantify IHC stain abundance within and around cells of the tumor microenvironment, enabling drug developers to build biomarker scoring strategies from scratch for most IHC stains and to precisely find those patients most responsive to treatment. PathAIs partnership with Roche streamlines the translation of these AI insights and scoring strategies into companion diagnostic development.
Drawing on our advanced computational pathology expertise, we're extending the impact of our Explore product suite, which enables us to seamlessly support AI-powered assay development, said Hisani Madison, VP of Precision Medicine and Medical Device Development. This advancement is poised to revolutionize biomarker-based drug development for new immunotherapies, antibody drug conjugates, and paving the way for the analysis of the next generation of targeted cancer therapies.
Accepted Abstracts at ASCO 2024
PathAI will be attending and presenting abstracts at the upcoming ASCO event in Chicago, IL. Visit PathAIs booth in the Innovation Hub (IH18) May 31- June 4, 2024 to meet our team, learn more about AI-powered pathology, and engage with our scientists and collaborators at their respective posters.
|
Abstract # |
Title |
|
8539 |
|
|
4519 |
Footnotes
1 PathExplore IOP and IHC Explore are for research use only. Not for use in diagnostic procedures.
About PathAI
PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAIs digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com.
Contact Details
SVM Public Relations and Marketing Communications
Maggie Naples
+1 401-490-9700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/pathai-expands-portfolio-of-ai-powered-products-announcing-pathexplore-iop-and-ihc-explore-ahead-of-asco-2024-944684717
PathAI
COMTEX_453056796/2655/2024-05-29T10:05:36
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.
